Revolution Medicines, Inc. Share Price
NASDAQ: RVMD | Large CapRevolution Medicines, Inc. Stock Performance
Open $197.89 | Prev. Close $197.09 | Circuit Range N/A |
Day Range $195.53 - $202.59 | Year Range $34.22 - $202.59 | Volume 90,137 |
Average Traded $199.10 |
Revolution Medicines, Inc. Share Price Today
As of 9 August 2026, Revolution Medicines, Inc.'s share price is $197.81. The stock opened at $197.89, compared to its previous close of $197.09. During today's trading session, Revolution Medicines, Inc.'s share price traded between $195.53 and $202.59, with an average price of $199.06. Over the past 52 weeks, the stock has recorded a high of $202.59 and a low of $34.22. In terms of performance, Revolution Medicines, Inc.'s share price has risen by 93.76% over the last six months and is up 420.96% on a year-on-year basis.
Revolution Medicines, Inc. Share Price Chart
Revolution Medicines, Inc. Stock Fundamentals & Key Indicators
Market Cap $37.61B | PE Ratio (TTM) -33.25 | Dividend Yield N/A |
EPS (TTM) $-5.95 | Revenue (TTM) N/A | Return On Equity (TTM) -69.35% |
Profit Margin N/A | Debt to Equity 0.18 | Quarterly Earnings Growth YoY -83.97% |
Revolution Medicines, Inc. Quarterly Profit & Loss
All figures in USD
Revolution Medicines, Inc. Annual Profit & Loss
All figures in USD
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Revolution Medicines, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $185.69 | $196.97 | +5.00% |
Jul 2026 | $186.56 | $187.59 | +0.24% |
Jun 2026 | $159.05 | $187.15 | +18.76% |
May 2026 | $141.50 | $157.59 | +9.28% |
Apr 2026 | $98.32 | $144.21 | +48.39% |
Mar 2026 | $100.93 | $97.18 | -4.81% |
Feb 2026 | $96.25 | $102.09 | +5.39% |
Jan 2026 | $79.83 | $96.87 | +21.60% |
Dec 2025 | $77.20 | $79.66 | +2.38% |
Nov 2025 | $58.93 | $77.81 | +32.28% |
Oct 2025 | $46.93 | $58.82 | +25.93% |
Sep 2025 | $38.33 | $46.71 | +23.02% |